2-(3-hydroxypropyl)-2-phenyl-1,3-dioxolane | 17851-46-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(3-hydroxypropyl)-2-phenyl-1,3-dioxolane
• 英文别名: 3-(2-phenyl-1,3-dioxolan-2-yl)propan-1-ol；4,4-ethylenedioxy-4-phenylbutyl alcohol；4-hydroxybutyrophenone ethylene ketal
• CAS: 17851-46-6
• 化学式: C₁₂H₁₆O₃
• mdl: MFCD19316358
• 分子量: 208.257
• InChiKey: VKVYQWCLOQMRMG-UHFFFAOYSA-N

物化性质

• 沸点：
  174-176 °C(Press: 10 Torr)
• 密度：
  1.125±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3-hydroxypropyl)-2-phenyl-1,3-dioxolane 在 吡啶 作用下， 以 丙酮 为溶剂， 生成 4-oxo-4-phenylbutyl acetate
  参考文献：
  名称：

  Dhokte, Ulhas P.; Rao, A. Somasekar, Organic Preparations and Procedures International, 1992, vol. 24, # 1, p. 13 - 20

  摘要：

  DOI：
• 作为产物：
  描述：

  2-[2-(methoxycarbonyl)ethyl]-2-phenyl-1,3-dioxolane 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 3.0h， 以91%的产率得到2-(3-hydroxypropyl)-2-phenyl-1,3-dioxolane
  参考文献：
  名称：

  使用可回收的氧铵盐脱氢全氟烷基酮

  摘要：

  描述了全氟烷基酮通过氧代铵盐 4-乙酰氨基-2,2,6,6-四甲基哌啶-1-四氟硼酸氧代铵（4-NHAc-TEMPO+BF4–，博比特盐，1）进行的新型脱氢反应。该反应在弱碱性条件下进行，似乎是全氟烷基酮所独有的。给出了这种不寻常转换的建议机制。反应的副产物 4-乙酰氨基-2,2,6,6-四甲基-1-哌啶基氧基 (1a) 可以很容易地回收并用于再生氧铵盐。

  DOI：

  10.1002/ejoc.201300392

文献信息

• Elevation of HDL cholesterol by
  申请人：American Home Products Corporation

  公开号：US05977170A1

  公开（公告）日：1999-11-02

  This invention relates to the treatment of atherosclerosis via raising the level of HDL cholesterol by administration of a compound of the formula ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 are independently hydrogen, C.sub.1 -C.sub.6 alkyl or --(CH.sub.2).sub.0-6 Ph where Ph is optionally substituted by halogen, cyano, nitro, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, trifluoromethyl, C.sub.1 -C.sub.6 alkoxycarbonyl, --CO.sub.2 H or OH; R.sub.4 and R.sub.5 are independently hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.8 cycloalkyl, or --(CH.sub.2).sub.0-6 Ar.sup.1 where Ar.sup.1 is phenyl, naphthyl, furanyl, pyridinyl or thenyl and Ar.sup.1 can be optionally substituted by halogen, cyano, nitro, C.sub.1 -C.sub.6 alkyl, phenyl, C.sub.1 -C.sub.6 alkoxy, phenoxy, trifluoromethyl, C.sub.1 -C.sub.6 alkoxycarbonyl, --CO.sub.2 H or OH; and Ar is phenyl, naphthyl, furanyl, pyridinyl or thienyl or Ar is optionally substituted by halogen, cyano, nitro, C.sub.1 -C.sub.6 alkyl, phenyl, C.sub.1 -C.sub.6 alkoxy, phenoxy, trifluoromethyl, C.sub.1 -C.sub.6 alkoxycarbonyl, --CO.sub.2 H or OH.

  这项发明涉及通过给予以下式化合物提高HDL胆固醇水平来治疗动脉粥样硬化：其中R.sup.1、R.sup.2和R.sup.3独立地为氢、C.sub.1 -C.sub.6烷基或--(CH.sub.2).sub.0-6苯，其中苯可以选择性地被卤素、氰基、硝基、C.sub.1 -C.sub.6烷基、C.sub.1 -C.sub.6烷氧基、三氟甲基、C.sub.1 -C.sub.6烷氧羰基、--CO.sub.2 H或OH取代；R.sub.4和R.sub.5独立地为氢、C.sub.1 -C.sub.6烷基、C.sub.3 -C.sub.8环烷基，或--(CH.sub.2).sub.0-6 Ar.sup.1，其中Ar.sup.1为苯基、萘基、呋喃基、吡啶基或噻吩基，Ar.sup.1可以选择性地被卤素、氰基、硝基、C.sub.1 -C.sub.6烷基、苯基、C.sub.1 -C.sub.6烷氧基、苯氧基、三氟甲基、C.sub.1 -C.sub.6烷氧羰基、--CO.sub.2 H或OH取代；Ar为苯基、萘基、呋喃基、吡啶基或噻吩基，或Ar可以选择性地被卤素、氰基、硝基、C.sub.1 -C.sub.6烷基、苯基、C.sub.1 -C.sub.6烷氧基、苯氧基、三氟甲基、C.sub.1 -C.sub.6烷氧羰基、--CO.sub.2 H或OH取代。
• Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06251926B1

  公开（公告）日：2001-06-26

  This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

  本发明提供了一种新颖的氧亚氨基烷酸衍生物，该衍生物具有优异的降糖和降脂作用，用于治疗糖尿病、高脂血症、胰岛素不敏感、胰岛素抵抗和葡萄糖耐量受损。
• Intramolecular β-Alkenylation of Cyclohexanones via Pd-Catalyzed Desaturation-Mediated C(sp³)–H/Alkyne Coupling
  作者：Chengpeng Wang、Nevin A. Naren、Pengfei Zheng、Guangbin Dong

  DOI：10.1021/jacs.0c02654

  日期：2020.5.13

  through direct coupling of C(sp3)-H bonds with unsaturated hydrocarbons represents an atom-economical and redox-neutral way for functionalizing chemically inert positions, such as those β to a carbonyl group. While most existing β-functionalization methods utilize a directing group (DG) strategy, here we report a Pd-catalyzed intramolecular β-alkenylation of ketones using alkynes as the coupling partner without

  通过 C(sp3)-H 键与不饱和烃的直接偶联形成位点选择性 CC 键代表了一种原子经济且氧化还原中性的方式，用于将化学惰性位置（例如 β 为羰基）官能化。虽然大多数现有的 β-官能化方法利用定向基团 (DG) 策略，但在这里我们报告了 Pd 催化的酮的分子内 β-烯基化，使用炔烃作为偶联伙伴，无需 DGs。在酮去饱和过程的介导下，该反应是氧化还原中性的，避免使用强酸或强碱。由此产生的 cis-5,6-融合自行车可以以优异的选择性进行多样化衍生。机理研究暗示了一种不寻常的“氢化物转移”链状途径，
• Studies on Non-Thiazolidinedione Antidiabetic Agents. 2. Novel Oxyiminoalkanoic Acid Derivatives as Potent Glucose and Lipid Lowering Agents.
  作者：Hiroshi Imoto、Yasuo Sugiyama、Hiroyuki Kimura、Yu Momose

  DOI：10.1248/cpb.51.138

  日期：——

  We previously reported that (Z)-2-4-[(5-methyl-2-phenyl-1, 3-oxazol-4-yl)methoxy]benzyloxyimino}-2-(4-phenoxyphenyl)acetic acid (3) showed potent glucose and lipid lowering effects in genetically obese and diabetic mice, KKAy. This compound also showed transcriptional activity for peroxisome proliferator-activated receptor (PPAR)-γ. We expanded on the structure–activity relationships of oxyiminoalkanoic acid derivatives based on this transcriptional activity (in vitro). Insertion of a carbon chain between the imino carbon and the carboxyl moiety of (Z)-2-4-[(5-methyl-2-phenyl-1, 3-oxazol-4-yl)methoxy]benzyloxyimino}-2-phenylacetic acid (2) resulted in a marked increase in transcriptional activity at PPARγ. In vivo potencies of synthesized compounds, which showed strong functional activity at PPARγ, were tested using KKAy mice. Among these compounds, (E)-4-4-[(5-methyl-2-phenyl-1, 3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyric acid (27) exhibited marked glucose and lipid lowering activity while showing no significant body weight gain. Compound (27) (TAK-559) showed favorable pharmacokinetic properties with good absorption and duration, and was considered as an attractive candidate for further evaluation.

  我们之前报道过，(Z)-2-4-[(5-甲基-2-苯基-1,3-恶唑-4-基)甲氧基]苄氧亚胺}-2-(4-苯氧基苯基)乙酸 (3) 在基因肥胖和糖尿病小鼠 KKAy 中表现出显著的降糖和降脂效果。该化合物还显示出对过氧化物酶体增殖物激活受体 (PPAR)-γ 的转录活性。我们基于这种转录活性（体外）扩展了氧亚胺烷酸衍生物的结构—活性关系。在 (Z)-2-4-[(5-甲基-2-苯基-1,3-恶唑-4-基)甲氧基]苄氧亚胺}-2-苯基乙酸 (2) 的亚胺碳与羧基之间插入碳链，显著提高了 PPARγ 的转录活性。合成化合物在 KKAy 小鼠中进行了体内效能测试，这些化合物在 PPARγ 上显示出强的功能活性。在这些化合物中，(E)-4-4-[(5-甲基-2-苯基-1,3-恶唑-4-基)甲氧基]苄氧亚胺}-4-苯基丁酸 (27) 展示了显著的降糖和降脂活性，同时未显示出明显的体重增加。化合物 (27) (TAK-559) 显示出良好的药代动力学特性，具备良好的吸收和持续时间，因此被认为是进一步评估的有吸引力的候选者。
• Oxyiminoalkanoic acid derivatives
  申请人：——

  公开号：US20030186985A1

  公开（公告）日：2003-10-02

  To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance. A compound represented by the formula: 1 wherein R 1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, —CO—, —CH(OH)— or a group represented by —NR 6 — wherein R 6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, —SO—, —SO 2 — or a group represented by —NR 7 — wherein R 7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R 2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R 3 is a hydroxy group, OR 8 (R 8 is an optionally substituted hydrocarbon group.) or NR 9 R 10 (R 9 and R 10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R 9 and R 10 combine together to form a ring); R 4 and R 5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R 4 may form a ring with R 2 ; provided that when R 1 is a ethoxymethyl, a C 1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R 3 is NR 9 R 10 ; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methylpyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof.

  提供一种新型的氧亚胺基脂肪酸衍生物，具有优异的降血糖和降血脂作用，并用于预防或治疗糖尿病、高脂血症、胰岛素不敏感、胰岛素抵抗和糖耐量受损。该化合物的结构式为1，其中R1是可选取的取代的碳氢化合物基团或可选取的取代的杂环基团；X是键，-CO-，-CH（OH）-或由-NR6-表示的基团（其中R6是氢原子或可选取的取代的烷基基团）；n是1到3的整数；Y是氧原子、硫原子、-SO-，-SO2-或由-NR7-表示的基团（其中R7是氢原子或可选取的烷基基团）；环A是苯环，可选取具有1到3个附加取代基团；p是1到8的整数；R2是氢原子、可选取的取代的碳氢化合物基团或可选取的取代的杂环基团；q是0到6的整数；m是0或1；R3是羟基、OR8（其中R8是可选取的取代的碳氢化合物基团）或NR9R10（其中R9和R10是相同或不同的基团，选自氢原子、可选取的取代的碳氢化合物基团、可选取的取代的杂环基团或可选取的取代的酰基，或R9和R10结合形成环）；R4和R5是相同或不同的基团，选自氢原子或可选取的取代的碳氢化合物基团，其中R4可以与R2形成环；但当R1为乙氧甲基、C1-3烷基、苯基或对甲氧基苯基且q=m=0时，R3为NR9R10；且不包括O-[2-氯-4-(2-喹啉基甲氧基)苯甲基]肟和[2-氯-4-(2-喹啉基甲氧基)苯甲基]-2-亚氨基丙酸甲酯；或其盐。